

GLAXOSMITHKLINE PLC  
Form 6-K  
February 24, 2010

**FORM 6-K**

**SECURITIES AND EXCHANGE COMMISSION**  
**Washington D.C. 20549**

**Report of Foreign Issuer**

**Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934**

For period ending February 24, 2010

**GlaxoSmithKline plc**  
(Name of registrant)

**980 Great West Road, Brentford, Middlesex, TW8 9GS**  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes  No

--

**Notification of Transactions of Directors and Persons Discharging Managerial Responsibility**

**Vesting of 2007 GlaxoSmithKline Performance Share Plan Awards**

The three-year performance period for the GlaxoSmithKline Performance Share Plan (the Performance Share Plan) awards made in 2007, which commenced on 1 January 2007, came to an end on 31 December 2009.

The Remuneration Committee considered the performance achieved in respect of the PSP awards and determined that the:

.  
awards granted to Executive Directors and CET members in office in 2007 were dependent on Total Shareholder Return (TSR) performance. The Company ranked at the median of the comparator group and therefore 35% of the awards subject to the TSR measure vested.

.  
awards granted in 2007 to senior executives who have since been appointed a CET member, were dependent in part on TSR performance and in part on EPS performance. Half of these awards lapsed as GSK's EPS performance conditions were not met, and 35% of the half of the awards subject to the TSR performance measure vested.

The following Performance Share Plan awards made to the Executive Directors and CET members in office in 2007, vested in part on 23 February 2010 and the balance of the award lapsed, as set out in the table below:

|                | <b>Awards vesting under<br/>TSR measure - 35% of<br/>award</b> |        |
|----------------|--|--------|
|                | <b>Ordinary Shares ADSs</b>                                    |        |
| Mr A Witty*    | 29,750   |        |
| Mr J S Heslop* | 36,750   |        |
| Mr M Slaoui*   |  | 24,150 |
| Mr J M Clarke  | 26,950   |        |
| Mr M Dunoyer   | 10,150   |        |
| Mr D Learmouth | 7,438  |        |
| Mr W C Louv    |  | 8,750  |
| Mr D J Phelan  |  | 13,475 |
| Mr D Pulman    |  | 8,750  |

\* denotes an Executive Director

Half of the award made in 2007 to senior executives who have since been appointed a CET member lapsed, the other half of the award vested in part (35%), the balance lapsed, on 23 February 2010 as set out in the table below:

|                 | <b>Awards that have not vested under<br/>EPS measure</b> | <b>Awards vesting under TSR measure - 35% of<br/>TSR portion of award</b> |
|-----------------|--|---|
|                 | <b>Ordinary Shares</b>                                   | <b>Ordinary Shares</b>  |
| Mr S M Bicknell | 4,440  | 1,554   |

|                |        |       |
|----------------|--------|-------|
| Mr E J Gray    | 5,900  | 2,065 |
| Mr D S Redfern | 5,900  | 2,065 |
| Mr J R         | 13,300 | 4,655 |
| Stephenne      |        |       |
| Ms C Thomas    | 4,440  | 1,554 |

The Company and PDMRs were advised of these transactions on 24 February 2010.

This notification is made in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).

**V Whyte**  
**Deputy Company Secretary**

24 February 2010

**Enquiries:**

UK Media enquiries: Philip Thomson (020) 8047 5502  
Claire Brough (020) 8047 5502  
Stephen Rea (020) 8047 5502  
Alexandra Harrison (020) 8047 5502

US Media enquiries: Nancy Pekarek (919) 483 2839  
Mary Anne Rhyne (919) 483 2839  
Kevin Colgan (919) 483 2839  
Sarah Alspach (919) 483 2839

European Analyst/Investor enquiries: David Mawdsley (020) 8047 5564  
Sally Ferguson (020) 8047 5543  
Gary Davies (020) 8047 5503

US Analyst/ Investor enquiries: Tom Curry (215) 751 5419  
Jen Hill Baxter (215) 751 7002

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

**GlaxoSmithKline plc**  
(Registrant)

Date: February 24, 2010

By: VICTORIA WHYTE

-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc